Compare Boston Scientific Corporation (BSX) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs ProShares UltraPro S&P500 — how do they compare? Boston Scientific Corporation trades at $42.65 (market cap $66.37B), while ProShares UltraPro S&P500 trades at $144.72. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | UPRO | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $108.14 | $150.93 |
52-Week Low | $42.63 | $89.29 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
UPRO is trading at $142.72, down 2.35% on the day, with technical indicators showing a bullish bias as moving averages signal strength while oscillators remain neutral. The stock faces immediate resistance at $145 and support at $141. Recent market sentiment reflects cautious optimism around S&P 500 performance, with analysts projecting potential index gains to 8,000 by year-end despite concerns about AI fatigue and elevated valuations.
The outlook for UPRO remains tied to broader market momentum, with earnings season potentially providing the next catalyst. Key risks include market volatility from Fed policy uncertainty and stretched valuations, while institutional positioning suggests continued confidence in large-cap US equities as the primary driver of returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
